New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, Ph.D., could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF ...
A case report describes over one year of complete remission in BRAF V600E-mutant histiocytic sarcoma using dabrafenib and ...
A preclinical study reports that the MEK inhibitor cobimetinib suppressed MAPK signaling, tumor cell invasion and ...
CHICAGO & SHANGHAI--(BUSINESS WIRE)--JS InnoPharm Ltd initiated the JSI-1187 plus dabrafenib combination dose-escalation phase of the Phase 1 study for patients with locally advanced or metastatic ...
The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does ...
Frequently affected by so-called oncogenic mutations, BRAF is implicated in several human cancers. In its normal state, the BRAF protein remains confined to an inactive form, through a mechanism of ...
Nuvectis Pharma, Inc. ( NVCT) reported positive expanded Phase 1b data for NXP200, an investigational second-generation BRAF inhibitor, in patients with recurrent or progressive BRAF V600-mutated ...
Newspoint on MSN
Emerging MAPK-targeted therapies for melanoma beyond BRAF V600
AI-generated illustration Recent research is spotlighting emerging therapeutic strategies for melanoma that target ...
This article is based on a poster originally authored by Qiuyuan Yang, Kaiqiang Hu, Lei Liu, Tingting Guo, Haiyan Gu, Pengwei Pan, and Fang He. The study aimed to unravel the underlying processes that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results